An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria.

Trial Profile

An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 According to an Alexion Pharmaceuticals media release, all patients from the phase 1b study have been successfully transitioned to the Phase 3 dosing regimen, after which plasma LDH levels have remained suppressed.
    • 11 Dec 2017 According to an Alexion Pharmaceuticals media release, results from Study 201 and Study 103 were presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition.
    • 11 Dec 2017 Results from Study 201 and Study 103 published in an Alexion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top